Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review
A Szymiczek, A Lone, MR Akbari - Clinical genetics, 2021 - Wiley Online Library
Breast cancer is a heterogeneous disease manifesting diversity at the molecular,
histological and clinical level. The development of breast cancer classification was centered …
histological and clinical level. The development of breast cancer classification was centered …
Improving prognosis of surrogate assay for breast cancer patients by absolute quantitation of Ki67 protein levels using Quantitative Dot Blot (QDB) method
J Hao, Y Lyu, J Zou, Y Zhang, S Xie, L Jing… - Frontiers in …, 2021 - frontiersin.org
Background Immunohistochemistry (IHC)-based surrogate assay is the prevailing method in
daily clinical practice to determine the necessity of chemotherapy for Luminal-like breast …
daily clinical practice to determine the necessity of chemotherapy for Luminal-like breast …
A Comparison Between Immunohistochemistry and mRNA Expression to Identify Human Epidermal Growth Factor Receptor 2–Low Breast Cancer
X Baez-Navarro, MR van Bockstal… - … of Pathology & …, 2024 - meridian.allenpress.com
Context.—Breast cancers (BCs) with low levels of human epidermal growth factor receptor 2
(HER2) expression (HER2-low) have become a targetable subset because of novel …
(HER2) expression (HER2-low) have become a targetable subset because of novel …
Genexpression molekularer Zielstrukturen im gepaarten Primärtumor, invasiven Tumor und Metastase beim Harnblasenkarzinom
C Böhmer - 2020 - archiv.ub.uni-heidelberg.de
Neue Untersuchungs-und Therapiemöglichkeiten haben das Potential, die Behandlung des
Urothelkarzinom zu verbessern. Voraussetzung ist, dass die Patienten identifiziert werden …
Urothelkarzinom zu verbessern. Voraussetzung ist, dass die Patienten identifiziert werden …